Retinal Dystrophy clinical trials at UCSF

3 in progress, 2 open to eligible people

Retinal dystrophy occurs when genetic changes lead to eye problems that can affect sight. UCSF is exploring innovative vision restoration techniques known as cone optogenetics. UCSF is additionally participating in a worldwide registry study focusing on retinal diseases caused by rare genetic changes.

Showing trials for

  • EyeConic: Qualification for Cone-Optogenetics

    open to all eligible people

    This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

    San Francisco, California and other locations

  • Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

    open to eligible people ages 4 years and up

    This is an international, multicenter study with two components: Registry - A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection - Enrollment is open to all genes on the RD Rare Gene List Natural History Study - A prospective, standardized, longitudinal Natural History Study - Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives 1. Genotype Characterization 2. Cross-Sectional Phenotype Characterization (within gene) 3. Establish a Link to My Retina Tracker Registry (MRTR) 4. Ancillary Exploratory Studies - Pooling of Genes Natural History Study Objectives 1. Natural History (within gene) 2. Structure-Function Relationship (within gene) 3. Risk Factors for Progression (within gene) 4. Ancillary Exploratory Studies - Pooling of Genes

    San Francisco, California and other locations

  • PRPF31 Mutation-Associated Retinal Dystrophy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.

    San Francisco, California and other locations

Our lead scientists for Retinal Dystrophy research studies include .

Last updated: